Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 5 | 2016 | 99 | 1.310 |
Why?
|
| Sarcoma | 3 | 2023 | 59 | 0.720 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 106 | 0.690 |
Why?
|
| Immunotherapy | 3 | 2021 | 27 | 0.650 |
Why?
|
| Lung Neoplasms | 5 | 2024 | 247 | 0.630 |
Why?
|
| Antibodies, Monoclonal | 3 | 2016 | 86 | 0.620 |
Why?
|
| Molecular Targeted Therapy | 2 | 2013 | 16 | 0.490 |
Why?
|
| Direct-to-Consumer Advertising | 1 | 2016 | 1 | 0.480 |
Why?
|
| Medical Oncology | 1 | 2016 | 23 | 0.470 |
Why?
|
| Melanoma | 1 | 2013 | 34 | 0.380 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 59 | 0.380 |
Why?
|
| Neutrophils | 2 | 2023 | 58 | 0.220 |
Why?
|
| Humans | 13 | 2024 | 12240 | 0.220 |
Why?
|
| Body Composition | 1 | 2024 | 43 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 105 | 0.200 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 7 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 11 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2021 | 29 | 0.160 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 101 | 0.160 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 61 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 70 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 7 | 0.140 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 37 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 42 | 0.130 |
Why?
|
| Biomarkers | 1 | 2018 | 294 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 17 | 0.120 |
Why?
|
| Prognosis | 3 | 2023 | 363 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 53 | 0.110 |
Why?
|
| Neoplasms | 1 | 2016 | 94 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2023 | 1467 | 0.110 |
Why?
|
| Adult | 3 | 2022 | 3557 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 3 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 10 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 12 | 0.100 |
Why?
|
| Forecasting | 1 | 2013 | 36 | 0.100 |
Why?
|
| United States | 1 | 2016 | 989 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 168 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2013 | 320 | 0.090 |
Why?
|
| Female | 7 | 2024 | 6974 | 0.090 |
Why?
|
| Middle Aged | 5 | 2024 | 4043 | 0.090 |
Why?
|
| Male | 6 | 2024 | 6815 | 0.080 |
Why?
|
| Child | 1 | 2013 | 614 | 0.080 |
Why?
|
| Body Weight | 2 | 2024 | 72 | 0.080 |
Why?
|
| Aged | 4 | 2024 | 4000 | 0.080 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 6 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2010 | 16 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 13 | 0.080 |
Why?
|
| Lymphocytes | 2 | 2023 | 30 | 0.080 |
Why?
|
| Young Adult | 1 | 2013 | 863 | 0.080 |
Why?
|
| Adolescent | 1 | 2013 | 989 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 41 | 0.080 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 7 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 817 | 0.070 |
Why?
|
| Animals | 1 | 2013 | 2092 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 4 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 5 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 4 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 1 | 2007 | 32 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 195 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2021 | 1478 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2024 | 221 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 10 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 12 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 726 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2022 | 16 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 4 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 9 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 22 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 47 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 99 | 0.040 |
Why?
|
| Patient Selection | 1 | 2021 | 111 | 0.040 |
Why?
|
| Time Factors | 1 | 2022 | 695 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2152 | 0.040 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 7 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 31 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 29 | 0.030 |
Why?
|
| Proteomics | 1 | 2018 | 39 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 152 | 0.030 |
Why?
|
| Mutation | 1 | 2018 | 175 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 35 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 85 | 0.030 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 2 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2015 | 4 | 0.030 |
Why?
|
| Hemoptysis | 1 | 2015 | 4 | 0.030 |
Why?
|
| Esophagitis | 1 | 2015 | 5 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 15 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 11 | 0.030 |
Why?
|
| Chest Pain | 1 | 2015 | 8 | 0.030 |
Why?
|
| Cough | 1 | 2015 | 7 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2015 | 25 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2015 | 15 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 22 | 0.030 |
Why?
|
| Palliative Care | 1 | 2015 | 53 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2015 | 827 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 4 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 8 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 10 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 23 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 97 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 281 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 28 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2007 | 16 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 40 | 0.020 |
Why?
|